by Nature Medicine
Developers are encouraged by the robust anti-tumor potency demonstrated by their novel chimeric receptor, the Dual-targeting Synthetic TCR and Antigen Receptor (D-STAR).
by Nature Medicine
Despite ongoing concerns, results from a French database study characterize the risk of secondary cancers after chimeric antigen receptor (CAR) T-cell therapy as very low.
by Blood Advances
Patients who have myeloid malignancies with TP53 mutations often fare poorly after hematopoietic stem cell transplantation (HSCT), but researchers say certain prognostic factors can help identify...
by Sophie Paczesny, MD, PhD
In celebration of Women’s History Month, ASTCT is proud to highlight the inspiring journeys of women making a profound impact in transplantation and cellular therapy. This spotlight features...
by LeAnne Kennedy, PharmD, BCOP, FHOPA, FASTCT
In celebration of Women’s History Month, ASTCT is proud to highlight the inspiring journeys of women making a profound impact in transplantation and cellular therapy. This spotlight features...
by Heather Hurley
ASTCT is powered by a dedicated team working behind the scenes to support members, advance the field and drive key initiatives. In this series, we highlight the people making it all happen.